Edition:
United Kingdom

Viking Therapeutics Inc (VKTX.OQ)

VKTX.OQ on NASDAQ Stock Exchange Capital Market

6.18USD
16 Feb 2018
Change (% chg)

$-0.05 (-0.80%)
Prev Close
$6.23
Open
$6.25
Day's High
$6.74
Day's Low
$6.16
Volume
624,336
Avg. Vol
265,559
52-wk High
$7.10
52-wk Low
$0.88

Select another date:

Fri, Feb 2 2018

BRIEF-Viking Therapeutics - Pricing Public Offering Of 11 Mln Shares At $5 Per Share

* VIKING THERAPEUTICS ANNOUNCES PRICING OF $55.0 MILLION PUBLIC OFFERING OF COMMON STOCK

BRIEF-Viking Therapeutics Announces Proposed Public Offering Of Common Stock

* VIKING THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Sphera Funds Management Ltd Reports 7.43 Pct Passive Stake In Viking Therapeutics

* SPHERA FUNDS MANAGEMENT LTD REPORTS 7.43 PERCENT PASSIVE STAKE IN VIKING THERAPEUTICS INC AS OF DECEMBER 7 - SEC FILING Source text : http://bit.ly/2kdgndu Further company coverage:

BRIEF-Viking Therapeutics Announces Proposed Public Offering Of Common Stock

* VIKING THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Viking Therapeutics Announces Positive Top-Line Results From Phase 2 Study Of VK5211 In Patients Recovering From Hip Fracture

* VIKING THERAPEUTICS ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 2 STUDY OF VK5211 IN PATIENTS RECOVERING FROM HIP FRACTURE

BRIEF-Viking Therapeutics reports third quarter 2017 financial results

* Viking Therapeutics reports third quarter 2017 financial results and provides corporate update

BRIEF-Viking Therapeutics files for sale of up to 6.9 mln shares by selling stockholder

* Viking Therapeutics Inc files for sale of up to 6.9 million shares of co's common stock by selling stockholder Lincoln Park Capital Fund Llc‍‍​ - SEC filing Source text: (http://bit.ly/2x3eVPr) Further company coverage:

BRIEF-VIKING THERAPEUTICS ANNOUNCES TOP-LINE RESULTS FROM PROOF-OF-CONCEPT STUDY OF VK0214

* VIKING THERAPEUTICS ANNOUNCES TOP-LINE RESULTS FROM PROOF-OF-CONCEPT STUDY OF VK0214 IN IN VIVO MODEL OF X-LINKED ADRENOLEUKODYSTROPHY (X-ALD)

BRIEF-VIKING THERAPEUTICS ANNOUNCES PURCHASE AGREEMENTS FOR UP TO $16.25 MILLION WITH LINCOLN PARK CAPITAL

* VIKING THERAPEUTICS ANNOUNCES PURCHASE AGREEMENTS FOR UP TO $16.25 MILLION WITH LINCOLN PARK CAPITAL

Select another date: